Recent research published in *Nature* has illuminated the role of genetic factors in the efficacy of weight-loss medications such as Wegovy and Mounjaro. The study reveals that individuals with specific genetic variations linked to appetite and digestion are more likely to experience significant weight loss when using these treatments. This discovery not only sheds light on the variability in patient responses to these drugs but also addresses the associated side effects that some users encounter.
The Role of Genetics in Weight Loss
This groundbreaking study involved data from approximately 15,000 participants who had previously undergone genetic testing through the company 23andMe. By analysing countless genetic variants, researchers were able to identify a correlation between certain genetic markers and the effectiveness of weight-loss drugs. Notably, they found that individuals possessing a specific genetic variant tend to lose more weight, averaging an additional 0.76 kg (1.6 lbs). Those with two copies of this gene may double their weight loss, demonstrating a significant genetic influence.
Professor Ruth Loos from the University of Copenhagen, who contributed to the research, highlighted that this genetic factor is particularly prevalent among individuals of European descent, with about 64% carrying at least one copy of the variant. In contrast, only 7% of African Americans possess this gene. Furthermore, the study identified another variant that appears to be linked to increased side effects, such as nausea and vomiting, which can severely affect up to 1% of users of Mounjaro.
Additional Factors Affecting Weight Loss
While the genetic component is significant, it is crucial to understand that genetics is just one aspect of a multifaceted equation. Dr. Marie Spreckley from the University of Cambridge pointed out that behavioural, clinical, and treatment-related factors play equally important roles in determining weight-loss outcomes. These include the patient’s diet, exercise habits, and the level of support they receive while on the medication.
Previous studies have indicated that women are more than twice as likely to achieve a 15% weight loss on Mounjaro compared to men, suggesting that gender also influences treatment efficacy. Age, ethnicity, and other health conditions can further complicate the landscape, with younger and white or Asian individuals generally experiencing more significant weight loss, although the underlying reasons for these disparities remain largely unexplained.
The Current Landscape of Weight-Loss Medications
In the UK, an estimated 1.6 million people have attempted to use weight-loss drugs over the past year, a figure that is anticipated to grow. Currently, the NHS prescribes Wegovy and Mounjaro only to a limited number of patients with obesity and related health complications. Most individuals purchase these medications privately through online pharmacies.
The potential for weight loss varies significantly among users, with clinical trials indicating an average weight reduction of 14% for semaglutide (Ozempic and Wegovy) and 20% for tirzepatide (Mounjaro). In the study referenced, participants lost an average of 11.7% of their body weight over approximately eight months, although some individuals reported losing as much as 30%.
The Future of Weight Loss Treatment
The research suggests that a more personalised approach to prescribing weight-loss medications—often referred to as “precision medicine”—could be on the horizon. This strategy would take into account genetic factors alongside other individual characteristics to tailor treatments more effectively. However, experts, including Professor Naveed Sattar from the University of Glasgow, caution that while these findings are fascinating, they are still far from being implemented in clinical practice. Significant further research is required to better understand the balance of benefits and risks associated with these emerging therapies.
Why it Matters
This research represents a pivotal step towards comprehending the complex interplay between genetics and weight-loss medications. As the prevalence of obesity continues to rise globally, understanding the factors that influence treatment efficacy is crucial for developing more effective and personalised interventions. The potential to tailor weight-loss strategies based on genetic predispositions could revolutionise treatment approaches, ultimately leading to better health outcomes for millions struggling with obesity.
